Eitherway, it's little too early for bad news on Rexista. It does make sense they got somebody in serious talks, and he wouldn't want to or isn't allowed to promote the product at a public conference. I've also said that in the past is that Odidi wouldn't need to be attending these conferences if they got a deal going. Other than Rexista and PODRAS or Regabaton, there really isn't anything significant to present at the conference anyway.
Naturally, IPCI is to be focused on Rexista and PODRAS right now. Since FDA had set a date for final approval on Rexista, September isn't that far off. It would make sense they partner up in preparation for potential launch end of year or early 2018.
I think right now we should be focusing on Rexista deal and the two ANDAs under MNK. Unlike some of the ANDAs Oxycodone have no patent protection that would prevent them from launching the product, I could see a partner wanting in on it.
Kepra and Glucophage I am not so sure about that. We might eventually see a deal on Glucophage. If this is a Rexista deal, you guys can get the Vegas party going.
News 
Market Data 
Discover 
AI
